High cost of research, development, and manufacturing...
The manufacturer of Casgevy is a biotech company called CRISPR Therapeutics. Casgevy carries a price tag of $2.2 million as a single-dose, one-time treatment regimen.20,21 Following Casgevy, the FDA also approved a second sickle cell therapy, Lyfgenia, marketed by another US pharmaceutical, Bluebird Bio, using a different technological approach (other than CRISPR/Cas9).22 While Casgevy is priced quite high at $2.2 million, the asking price of Lyfgenia is $3.1 million.20,21 It is hoped that, in time, the exorbitant price of research and development will decrease to improve accessibility to more patients.
